Kanabo Group Plc.
("Kanabo" or the "Company")
Launch of two new medical cannabis products
& testing of the new IT Cannabis Platform
Kanabo Group, is pleased to announce the launch of two new medical cannabis extract formulas for inhalation, designed specifically to fill a gap in the market for premium products for patients with severe pain. The new formulas, available in versions suitable for day and evening use, will be branded as a Kanabo-Noidecs partnership with LYPHE Group and used with the VapePod, containing high levels of THC, low CBD, and cannabis naturally derived terpenes. The launch will broaden Kanabo's vape offering to the market and is an additional step for the company to build a robust product offering to all eligible patients in the UK. These new formulas will be available from next week to eligible patients via Dispensary Green pharmacy.
Further to the above, Kanabo Group is committed to increasing patient access to prescribed medical cannabis in the UK by developing a new platform using its recently acquired UK subsidiary, The GP Service Ltd. The company is pleased to announce that all the regulatory approvals have been obtained, and the testing stage of the platform has begun. Additional updates will be provided in due course.
Dr Mehran Afshar, Clinical Director of Kanabo Group:
"We are committed to improving patient access to prescribed medical cannabis through innovative technology and telemedicine services. Our new medical cannabis extract formulas for inhalation offer patients suffering from severe pain a premium option for managing their symptoms without the negative side effects of traditional cannabis flowers."
For further information, please visit http://www.kanabogroup.com/ :
| Kanabo Group Plc |
|
| Avihu Tamir, CEO | |
| Peterhouse Capital Ltd (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
| Eran Zucker | |
| Peterhouse Capital Ltd (Corporate Broker) | |
| Lucy Williams / Charles Goodfellow | |
About Kanabo Group Plc
Kanabo Group Plc is a leading developer and distributor of cannabis-derived products and inhalation technologies for medical patients and wellness consumers. The company is the first medicinal cannabis company to IPO on the London Stock Exchange and is made up of supply-chain specialist subsidiaries, including:
● The GP Service - a Kanabo Group Plc wholly owned, NHS-approved online telehealth provider offering video consultations, online prescriptions, treatment forms and access to primary care services.
● Kanabo Research Ltd - a wholly owned subsidiary responsible for Medical Device Development, Medical Cannabis formulation R&D, regulation and quality assurance procedures.
● Kanabo Agritec Ltd - a partly owned subsidiary, Cannabis Grow Consultancy firm that provides a comprehensive technology solution for controlled farming, including state-of-the-art irrigation and fertigation automation, facility planning and support services. This will provide high-quality raw materials for Kanabo's formulas and product line.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
